Breast Cancer Research Program

摘要：乳腺癌的治疗 乳腺癌计划（BC）是基础、转化、人口和临床研究的产物。 自1992年以来，LCCC乳腺癌孢子一直得到资助。LCCC投资 教师和基础设施支持该国首屈一指的临床和研究乳房计划之一， 在过去十年中进行了重要的跨学科研究，成员上升到国家领导层 岗位这种临床、基础和流行病学研究的结合是乳腺癌的标志。 计划，并反映在对教师和资源的投资，包括在过去5年， 超过1000万美元的基因组学/测序资源用于机构和大型多中心试验。这 承诺反映在面向患者的机构试验中，这些试验检查乳腺癌的临床意义 亚型以及LCCC领导的合作组织为基础的研究，通过翻译乳腺癌 癌症研究联盟（TBCRC）和AURORA-US项目（https：auroraus.org），一个多中心， 多平台分析转移瘤中的DNA、RNA和其他改变，与匹配的原发灶相比 肿瘤的对卡罗莱纳乳腺癌研究（CBCS）的纵向和特殊投资代表了 有史以来规模最大、注释最多的以人口为基础的研究， 乳腺癌，行为和结果。CBCS在本周期内获得了额外的500万美元投资， 为社区提供更多的了解全方位的乳腺癌研究， 基因组学/遗传学到卫生服务。该计划的战略目标包括：1）基因组和遗传分析， 转移性和原发性乳腺癌，2）使用鼠模型的实验室到床边方法，3）转化 基于人类组织相关科学的发现和策略，4）临床试验和人群- 基于研究，利用和应用可持续发展科学和社区投入， 差距。BC成员包括临床医生，基础研究人员，统计学家，生物信息学家，流行病学家， 和卫生服务科学家。不列颠哥伦比亚省长期关注北卡罗来纳州的少数民族差异， 该计划开创性地发现了年轻非洲人三阴性乳腺癌（TNBC）的高发病率， 美国人，随后的分子分析显示的差距更加惊人，令人惊讶的是， 研究发现，生存率最大的种族差异是患有激素受体阳性疾病的女性， 他们获得护理和坚持治疗是关键。BC计划由21名成员组成，他们是 与北卡罗来纳大学教堂山分校和附属机构的10个基础科学和5个临床部门有关。 在上一个资助期间，项目成员发表了494篇与癌症相关的文章，其中56%是 15%为方案内（57%为协作）。2019年，我们的项目成员 在与癌症相关的校外资助中获得了总计810万美元（直接成本）的赠款，其中包括400万美元（直接成本） 来自NCI和180万美元的其他同行评审资金。

ABSTRACT: BREAST CANCER PROGRAM The Breast Cancer Program (BC) was an outgrowth of the basic, translational, population and clinical research of the LCCC Breast Cancer SPORE, which has been continuously funded since 1992. LCCC investment in faculty and infrastructure supports one of the country’s premier clinical and research breast programs, performing important interdisciplinary research in the past decade with members rising to national leadership positions. This knitting together of clinical, basic, and epidemiologic research is the hallmark of the Breast Program, and is reflected in the investment in faculty and resources fostered by including, in the last 5 years, over $10M in genomics/sequencing resources used for institutional as well as large multicenter trials. This commitment is reflected in patient-facing institutional trials examining clinical implications of breast cancer subtypes as well as LCCC leadership of collaborative tissue-based studies through the Translational Breast Cancer Research Consortium (TBCRC) and AURORA-US Project (https://auroraus.org), a multicenter, multiplatform analysis of DNA, RNA, and other alterations in metastases compared with matched primary tumors. The longitudinal and exceptional investment in the Carolina Breast Cancer Studies (CBCS) represents the largest and most heavily annotated population-based study ever performed addressing racial disparities in breast cancer, behavior and outcome. CBCS has received an additional $5M investment in this cycle and is providing the community with an increased understanding of the full range of breast cancer research from genomics /genetics to health services. Program strategic goals include: 1) genomic and genetic analyses of metastatic and primary breast cancers, 2) bench-to-bedside approaches using murine models, 3) translational discovery and strategies based on human tissue-based correlative science, 4) clinical trials and population- based studies leveraging and applying UNC science and community input to address the root causes of disparities. BC members include clinicians, basic researchers, statisticians, bioinformaticians, epidemiologists, and health services scientists. BC has long-term interest in North Carolina’s minority disparities, following the program’s seminal discoveries of the high incidence of triple negative breast cancer (TNBC) in younger African Americans, the subsequent molecular analysis showing the disparity is even more striking, and the surprising finding that the largest racial disparity in survival is in women with hormone receptor-positive disease, for whom access to care and adherence to treatment are key. The BC Program consists of 21 members who are associated with 10 basic science and 5 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, program members published 494 cancer-related articles, of which 56% were inter-programmatic and 15% were intra-programmatic (57% collaborative). In 2019, our program members held grants totaling $8.1M (direct cost) in cancer-relevant extramural funding, including $4.0M (direct costs) from the NCI and $1.8M other peer-reviewed funding.